Karyopharm Therapeutics (KPTI) Receivables (2016 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Receivables came in at $26.2 million in Q4 2025, down 14.91% YoY from $30.8 million in Q4 2024, and down 17.88% on a QoQ basis from $31.9 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Receivables (2016 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 8 years of Receivables data on file, last reported at $26.2 million in Q4 2025.
- Quarterly Receivables fell 14.91% year-over-year to $26.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.2 million (down 14.91% YoY) and the FY2025 annual result came in at $26.2 million, down 14.91% from the prior year.
- Receivables eased to $26.2 million in Q4 2025, from $31.9 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $47.1 million in Q4 2022 to a low of $17.8 million in Q1 2021.
- A 5-year average of $29.5 million and a median of $30.9 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables surged 109.3% — and 2023, when it tumbled 42.74%.
- Tracing KPTI's Receivables over 5 years: stood at $22.5 million in 2021, then surged by 109.3% to $47.1 million in 2022, then plunged by 42.74% to $27.0 million in 2023, then advanced by 14.11% to $30.8 million in 2024, then fell by 14.91% to $26.2 million in 2025.
- The last three Receivables figures came in at $26.2 million (Q4 2025), $31.9 million (Q3 2025), and $32.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Karyopharm Therapeutics | 55.27 Mn | 55.27 Mn | 32.35 Mn | 29.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.87 Mn |
| Dec 31, 2025 | 26.18 Mn |
| Sep 30, 2025 | 31.88 Mn |
| Jun 30, 2025 | 32.93 Mn |
| Mar 31, 2025 | 35.24 Mn |
| Dec 31, 2024 | 30.77 Mn |
| Sep 30, 2024 | 31.78 Mn |
| Jun 30, 2024 | 38.00 Mn |
| Mar 31, 2024 | 31.08 Mn |
| Dec 31, 2023 | 26.96 Mn |
| Sep 30, 2023 | 37.92 Mn |
| Jun 30, 2023 | 32.28 Mn |
| Mar 31, 2023 | 35.20 Mn |
| Dec 31, 2022 | 47.09 Mn |
| Sep 30, 2022 | 27.45 Mn |
| Jun 30, 2022 | 23.48 Mn |
| Mar 31, 2022 | 24.99 Mn |
| Dec 31, 2021 | 22.50 Mn |
| Sep 30, 2021 | 18.75 Mn |
| Jun 30, 2021 | 17.89 Mn |